Thank you for donating!

You can donate using the following services.

Annual Family Conference

Our Annual Family Conference and Interactive Workshop on Niemann-Pick Diseases is the largest event in the NPUK calendar, bringing together affected individuals, families, health and research professionals under one roof.

This year we returned to Wyboston Lakes, Bedfordshire, over the weekend of 20th-22nd September 2019, to celebrate our 26th Conference! Wyboston Lakes is one of our favourite locations, with many memories made over the years, and we look forward to welcoming friends old and new, those newly diagnosed, living with Niemann-Pick or those that have experienced bereavement. This year’s Conference once again offered the opportunity to hear the latest developments regarding therapies and clinical trials for ASMD Niemann-Pick disease types A and B, and Niemann-Pick disease type C, plus related care issues, breakout sessions and workshops. Individuals and families wishing to attend should fill out the form, here.

The Interactive Workshop on Niemann-Pick Diseases, an event for professional delegates only, took place on Friday 21st September. Hosted by Professor Fran Platt, University of Oxford, the meeting will feature clinical and scientific presentations and workshops on relevant topics, including clinical management, research and potential therapies. Clinicians and health professionals wishing to attend, should fill out the form here. 

If you would like further information on the Annual Family Conference & Interactive Workshop please contact NPUK directly by email at: info@npuk.org, or by phone on: 0191 415 0693. 

Latest news

14.10.19

Study VTS301 – Study Resumption in France

Study Title: A Phase 2b/3 Prospective, Randomized, Double-Blind, Sham-Controlled Trial of VTS-270 (2-hydroxypropyl-β-cyclodextrin) in Subjects with Neurologic Manifestations of Niemann-Pick Type C1 (NPC1) Disease...

Read more

13.09.19

CTD Holdings Announces FDA Approval of US Expanded Access Treatment Program in Niemann-Pick Disease Type C

ALACHUA, FL–(Businesswire)–13 September 2019–CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, today announced that the company will provide Trappsol® Cyclo™, its proprietary hydroxypropyl beta cyclodextrin drug, to a pediatric patient diagnosed with Niemann-Pick Disease Type C...

Read more
View all news Subscribe